Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 10/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420390 | 0.92 | S1PR1 (0.67) | S1PR1S1PR5S1PR3 | |
| SCHEMBL13497727 | 0.89 | S1PR1 (0.53) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL10300800 | 0.86 | S1PR1 (0.52) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL1420177 | 0.85 | S1PR1 (0.55) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2121776 | 0.85 | S1PR1 (0.57) | S1PR1S1PR5S1PR3CYP3A4CYP2C9 | |
| SCHEMBL2132488 | 0.84 | S1PR1 (0.57) | S1PR1S1PR5S1PR3KCNH2 | |
| SCHEMBL1420386 | 0.82 | S1PR1 (0.58) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2133258 | 0.81 | S1PR1 (0.67) | S1PR1S1PR5S1PR3 | |
| SCHEMBL2135984 | 0.81 | S1PR1 (0.56) | S1PR1S1PR5S1PR3 | |
| SCHEMBL13540039 | 0.80 | S1PR1 (0.70) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217028-B2 | 1,2,4-oxadiazole indole compounds | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-8217028-B2 | 1,2,4-oxadiazole indole compounds | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2297139-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| WO-2009153307-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153307-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029729-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | S1PR1 2320/4885S1PR5 1843/4885S1PR3 1694/4885 |
| US-20100010053-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | S1PR1 2320/4885S1PR5 1843/4885S1PR3 1694/4885 |
| US-20110086839-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | S1PR1 2320/4885S1PR5 1843/4885S1PR3 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.